エピソード

  • Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances

    Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances
    2025/06/10

    Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    58 分
  • Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit

    Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit
    2025/05/18

    Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches. 

    CME information and select publications here.
    続きを読む 一部表示
    50 分
  • EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit

    EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit
    2025/04/30

    Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer. 

    CME information and select publications here.
    続きを読む 一部表示
    52 分
  • Oncology Nursing Edition: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress

    Oncology Nursing Edition: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress
    2025/04/26

    Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events.

    NCPD information and select publications here.

    続きを読む 一部表示
    1 時間 33 分
  • First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor

    First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor
    2025/04/10

    Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer.

    CME information and select publications here.

    続きを読む 一部表示
    57 分
  • EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

    EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
    2025/02/06

    Dr Enriqueta Felip from the Vall d’Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer.

    CME information and select publications here
    続きを読む 一部表示
    1 時間
  • Cases from the Community: Integrating New Research Findings into Current Practice — Lung Cancer

    Cases from the Community: Integrating New Research Findings into Current Practice — Lung Cancer
    2024/12/13

    Dr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer.
    続きを読む 一部表示
    48 分
  • Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer

    Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer
    2024/12/11

    Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer.
    続きを読む 一部表示
    59 分